LLY

926.07

+0.34%↑

JNJ

186.46

-0.33%↓

UNH

329.46

+0.06%↑

NVS

126.06

+0.47%↑

ABT

123.82

-1.94%↓

LLY

926.07

+0.34%↑

JNJ

186.46

-0.33%↓

UNH

329.46

+0.06%↑

NVS

126.06

+0.47%↑

ABT

123.82

-1.94%↓

LLY

926.07

+0.34%↑

JNJ

186.46

-0.33%↓

UNH

329.46

+0.06%↑

NVS

126.06

+0.47%↑

ABT

123.82

-1.94%↓

LLY

926.07

+0.34%↑

JNJ

186.46

-0.33%↓

UNH

329.46

+0.06%↑

NVS

126.06

+0.47%↑

ABT

123.82

-1.94%↓

LLY

926.07

+0.34%↑

JNJ

186.46

-0.33%↓

UNH

329.46

+0.06%↑

NVS

126.06

+0.47%↑

ABT

123.82

-1.94%↓

Search

CareDx Inc

Cerrado

SectorSanidad

15.14 -0.85

Resumen

Variación precio

24h

Actual

Mínimo

14.39

Máximo

16.58

Métricas clave

By Trading Economics

Ingresos

1.8M

-8.6M

Ventas

2M

87M

P/B

Media del Sector

14.067

77.256

Margen de beneficios

-9.885

Empleados

644

EBITDA

9.3M

-4M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+23.97% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

85M

786M

Apertura anterior

15.99

Cierre anterior

15.14

Noticias sobre sentimiento de mercado

By Acuity

38%

62%

128 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

CareDx Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 nov 2025, 23:51 UTC

Ganancias

CoreCivic Cuts Fiscal Year Guidance Amid Efforts to Launch New Detention Facilities

5 nov 2025, 23:10 UTC

Ganancias

DBS Third Quarter Net Dips 2.0%

5 nov 2025, 22:55 UTC

Ganancias

Arm Holdings 2Q Profit Climbs on Record Demand

5 nov 2025, 22:23 UTC

Ganancias

NAB's Annual Profit Falls 2.9% Amid Higher Costs, Credit Impairments -- Update

5 nov 2025, 23:52 UTC

Ganancias

United Overseas Bank 3Q Net Interest Income S$2.265B Vs. $2.46B >U11.SG

5 nov 2025, 23:49 UTC

Ganancias

United Overseas Bank 3Q Total Income S$3.40B Vs. S$3.83B >U11.SG

5 nov 2025, 23:49 UTC

Ganancias

United Overseas Bank 3Q Net S$443M Vs. Net S$1.61B >U11.SG

5 nov 2025, 23:45 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen, U.S. Tech Rebound -- Market Talk

5 nov 2025, 23:42 UTC

Charlas de Mercado

Gold Edges Lower Amid Reduced Odds of Fed Rate-Cut -- Market Talk

5 nov 2025, 23:12 UTC

Ganancias

Nutrien 3Q Adj EPS 97c >NTR.T

5 nov 2025, 23:11 UTC

Ganancias

Nutrien: Initiating Review of Strategic Alternatives for Phosphate Business >NTR.T

5 nov 2025, 23:10 UTC

Ganancias

Nutrien 3Q Sales $6.01B >NTR.T

5 nov 2025, 23:10 UTC

Charlas de Mercado
Ganancias

AppLovin Says Conversion Rate Is Biggest Growth Lever -- Market Talk

5 nov 2025, 23:10 UTC

Ganancias

Nutrien 3Q EPS 96c >NTR.T

5 nov 2025, 23:04 UTC

Ganancias

Qualcomm Stock Slides After Earnings Beat -- Barrons.com

5 nov 2025, 23:03 UTC

Charlas de Mercado

Macklem: Canada's Regulatory Overlap Turns Off Foreign Investors -- Market Talk

5 nov 2025, 22:55 UTC

Charlas de Mercado

Macklem Says Inflation and Productivity Are Intertwined -- Market Talk

5 nov 2025, 22:55 UTC

Ganancias

AppLovin Reports Strong Earnings. The Stock Is Up. -- Barrons.com

5 nov 2025, 22:51 UTC

Ganancias

DBS 3Q Total Income S$5.93B, Up 3% on Year >D05.SG

5 nov 2025, 22:50 UTC

Ganancias

DBS 3Q Net S$2.95B, Down 2.0% on Year >D05.SG

5 nov 2025, 22:44 UTC

Adquisiciones, fusiones, absorciones

Pfizer Preps Improved Offer in Metsera Bidding War -- Update

5 nov 2025, 22:43 UTC

Charlas de Mercado
Ganancias

NAB's Flat Dividend Disappoints Bears at Jarden -- Market Talk

5 nov 2025, 22:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 nov 2025, 22:36 UTC

Charlas de Mercado

Macklem Warns Structural Adjustment Means Slow Canadian Growth -- Market Talk

5 nov 2025, 22:20 UTC

Charlas de Mercado

Bank of Canada Says Budget Plan Identifies Economy's Biggest Weakness -- Market Talk

5 nov 2025, 22:12 UTC

Adquisiciones, fusiones, absorciones

Pfizer: Will Take Action to Preserve Rights Under Previously-Signed Agreement >PFE

5 nov 2025, 22:11 UTC

Adquisiciones, fusiones, absorciones

Pfizer: Confident in Merits of Claims, Belief Metsera Has Acted in Breach of Contractual Obligations >PFE

5 nov 2025, 22:11 UTC

Adquisiciones, fusiones, absorciones

Pfizer Responds to Delaware Chancery Court Ruling

5 nov 2025, 22:01 UTC

Ganancias

Great-West Lifeco 3Q Net C$1.16B >GWO.T

5 nov 2025, 22:01 UTC

Ganancias

Great-West Lifeco 3Q Adj EPS C$1.33 >GWO.T

Comparación entre iguales

Cambio de precio

CareDx Inc previsión

Precio Objetivo

By TipRanks

23.97% repunte

Estimación a 12 Meses

Media 18 USD  23.97%

Máximo 22 USD

Mínimo 14 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

2

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.77 / 18.49Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

128 / 374 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat